These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35328741)

  • 21. SCF
    Sugiyama S; Yumimoto K; Inoue I; Nakayama KI
    Genes Cells; 2019 May; 24(5):354-365. PubMed ID: 30838725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stringent Control of NFE2L3 (Nuclear Factor, Erythroid 2-Like 3; NRF3) Protein Degradation by FBW7 (F-box/WD Repeat-containing Protein 7) and Glycogen Synthase Kinase 3 (GSK3).
    Kannan MB; Dodard-Friedman I; Blank V
    J Biol Chem; 2015 Oct; 290(43):26292-302. PubMed ID: 26306035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
    Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
    Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FBXW7 is involved in Aurora B degradation.
    Teng CL; Hsieh YC; Phan L; Shin J; Gully C; Velazquez-Torres G; Skerl S; Yeung SC; Hsu SL; Lee MH
    Cell Cycle; 2012 Nov; 11(21):4059-68. PubMed ID: 23095493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
    Chen X; Li XY; Long M; Wang X; Gao ZW; Cui Y; Ren J; Zhang Z; Liu C; Dong K; Zhang H
    Neoplasma; 2018; 65(2):201-209. PubMed ID: 29534580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
    Saffie R; Zhou N; Rolland D; Önder Ö; Basrur V; Campbell S; Wellen KE; Elenitoba-Johnson KSJ; Capell BC; Busino L
    Cancer Res; 2020 Jun; 80(12):2498-2511. PubMed ID: 32350066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A widely used pan-isoform-FBXW7 antibody used in cell cycle studies does not detect FBXW7.
    Ennis H; McDonald DM
    Cell Cycle; 2023 Jun; 22(11):1380-1390. PubMed ID: 37183425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis.
    Cao J; Ge MH; Ling ZQ
    Medicine (Baltimore); 2016 Feb; 95(7):e2496. PubMed ID: 26886596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A colon cancer-derived mutant of Krüppel-like factor 5 (KLF5) is resistant to degradation by glycogen synthase kinase 3β (GSK3β) and the E3 ubiquitin ligase F-box and WD repeat domain-containing 7α (FBW7α).
    Bialkowska AB; Liu Y; Nandan MO; Yang VW
    J Biol Chem; 2014 Feb; 289(9):5997-6005. PubMed ID: 24398687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plk2 regulates centriole duplication through phosphorylation-mediated degradation of Fbxw7 (human Cdc4).
    Cizmecioglu O; Krause A; Bahtz R; Ehret L; Malek N; Hoffmann I
    J Cell Sci; 2012 Feb; 125(Pt 4):981-92. PubMed ID: 22399798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation.
    Xi Z; Yao M; Li Y; Xie C; Holst J; Liu T; Cai S; Lao Y; Tan H; Xu HX; Dong Q
    Cell Death Dis; 2016 Jun; 7(6):e2252. PubMed ID: 27253416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of CDC4/FBXW7 in gastric carcinoma.
    Milne AN; Leguit R; Corver WE; Morsink FH; Polak M; de Leng WW; Carvalho R; Offerhaus GJ
    Cell Oncol; 2010; 32(5-6):347-59. PubMed ID: 20448329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct Interactions of EBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer.
    Wang Y; Zhang P; Wang Y; Zhan P; Liu C; Mao JH; Wei G
    Cancer Res; 2017 Apr; 77(8):1983-1996. PubMed ID: 28209614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
    Baxter JS; Brough R; Krastev DB; Song F; Sridhar S; Gulati A; Alexander J; Roumeliotis TI; Kozik Z; Choudhary JS; Haider S; Pettitt SJ; Tutt ANJ; Lord CJ
    Mol Oncol; 2024 Feb; 18(2):369-385. PubMed ID: 37866880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis.
    Cheng X; Hao Y; Shu W; Zhao M; Zhao C; Wu Y; Peng X; Yao P; Xiao D; Qing G; Pan Z; Yin L; Hu D; Du HN
    J Biol Chem; 2017 Jun; 292(22):9022-9033. PubMed ID: 28442573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic ubiquitination of the mitogen-activated protein kinase kinase (MAPKK) Ste7 determines mitogen-activated protein kinase (MAPK) specificity.
    Hurst JH; Dohlman HG
    J Biol Chem; 2013 Jun; 288(26):18660-71. PubMed ID: 23645675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent insight into the role of FBXW7 as a tumor suppressor.
    Yumimoto K; Nakayama KI
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early growth response-1 is a new substrate of the GSK3β-FBXW7 axis.
    Yin L; Zhang J; Sun Y
    Neoplasia; 2022 Dec; 34():100839. PubMed ID: 36240645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7.
    Xu Y; Sengupta T; Kukreja L; Minella AC
    J Biol Chem; 2010 Nov; 285(45):34439-46. PubMed ID: 20826802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma.
    Zhang E; Chen S; Tang H; Fei C; Yuan Z; Mu X; Qin Y; Liu H; Fan Y; Tan M; Wang X
    Cancer Sci; 2022 Jan; 113(1):91-108. PubMed ID: 34741373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.